Breaking
BreezeBio raises $60M Series B - Feb 2026 GenEdit officially rebrands to BreezeBio NanoGalaxy platform hits first milestone in $644M Roche/Genentech deal - May 2025 BRZ-101 advancing toward IND-enabling studies for Type 1 Diabetes $57M Sarepta Therapeutics partnership for neuromuscular gene editing Total funding: $118.5M raised since founding NIH TARGETED Challenge Phase I winner - Dec 2023 CEO Dr. Kunwoo Lee named Forbes 30 Under 30 - 2017 Eli Lilly leads $24M Series A1 in January 2024 BreezeBio raises $60M Series B - Feb 2026 GenEdit officially rebrands to BreezeBio NanoGalaxy platform hits first milestone in $644M Roche/Genentech deal - May 2025 BRZ-101 advancing toward IND-enabling studies for Type 1 Diabetes $57M Sarepta Therapeutics partnership for neuromuscular gene editing Total funding: $118.5M raised since funding NIH TARGETED Challenge Phase I winner - Dec 2023 CEO Dr. Kunwoo Lee named Forbes 30 Under 30 - 2017 Eli Lilly leads $24M Series A1 in January 2024
BreezeBio - Precision Genetic Medicines
Brisbane, CA. Nine years. Zero viruses. One very specific problem.
Biotech · Gene Therapy · Drug Delivery

BreezeBio

Formerly GenEdit. Always non-viral.

BreezeBio builds polymer nanoparticles that deliver genetic medicines to exact tissues - without viral vectors, without one-and-done dosing limits, and without provoking the immune system. Backed by Roche, Eli Lilly, and Sequoia. Founded in a Berkeley PhD lab. Now running its own drug pipeline.

Non-Viral Delivery NanoGalaxy CRISPR Delivery Gene Therapy Autoimmune Series B
$118.5M Total Raised
$644M Roche Partnership
~64 Employees
2016 Founded

The Lab That Refused to Use a Virus

A lab in Brisbane, California is running one of gene therapy's quietest experiments: can you fix a broken immune system using nothing but precisely engineered plastic? Not plastic in the grocery bag sense - polymer in the molecular architecture sense, shaped at nanometer scale to slip past biological defenses and deliver a genetic payload exactly where you want it.

BreezeBio - until February 2026, known as GenEdit - has been running this experiment since 2016. In that time, they have signed deals worth up to $701 million with Roche/Genentech and Sarepta Therapeutics, raised $118.5 million from investors including Eli Lilly and Sequoia Capital, and are now developing their own therapeutic for Type 1 Diabetes. They have 64 people to do it. There are pharma companies with larger cafeteria staffs.

The rebrand is not a marketing exercise. It is a declaration. BreezeBio is no longer content to supply the delivery truck. They want to drive it to market.
On GenEdit's transformation into BreezeBio, Feb 2026

The name change from GenEdit to BreezeBio signals something concrete: a strategic shift from delivery-platform licensor to therapeutic developer. For nine years, the company perfected the plumbing. Now they are building what goes inside it.

Gene Therapy's Dirty Secret

The promise of gene therapy is simple: find the broken gene, fix it, move on. The reality is messier. For most of its history, gene therapy has relied on viruses - typically adeno-associated viruses (AAVs) - to carry genetic payloads into cells. Viruses are, after all, the evolutionary experts at injecting DNA into cells. They have had four billion years to practice.

But viruses come with serious engineering constraints. The immune system remembers them. Once you dose a patient with an AAV-based therapy, you generally cannot dose them again - the body has built antibodies against the viral shell. Viral vectors also have tight payload size limits and can only reach certain tissues effectively. And they are genuinely hard to manufacture at scale without contamination risks.

The hard limit: AAV-based gene therapies are typically one-shot treatments. If the first dose is not enough - or if the patient develops over time - there is no second chance. For chronic diseases that evolve across a lifetime, this is not a solution. It is a partial answer.

Lipid nanoparticles - the technology behind COVID-19 mRNA vaccines - partially solved this. But they have their own problems: they accumulate in the liver by default, struggle to reach other tissues reliably, and can trigger inflammatory responses at higher doses. The field needed something more flexible, more tissue-specific, and less immunogenic. That is the gap BreezeBio has spent a decade filling.

The gene therapy field solved the medicine. It still has not solved the mailroom. BreezeBio is building the mailroom.
On the gene delivery problem

Two PhDs and a Polymer Library

Dr. Kunwoo Lee and Dr. Hyo Min Park met in the bioengineering labs at UC Berkeley. Lee was inventing CRISPR delivery technologies for his PhD thesis. Park was co-inventing CRISPR-12a technology that would later be licensed to Editas Medicine. In 2016, they looked at the gene delivery landscape and concluded that nobody was solving the problem correctly.

Dr. Kunwoo Lee
CEO & Co-Founder
PhD in Bioengineering, UC Berkeley. Inventor of multiple CRISPR delivery technologies. Forbes 30 Under 30 (2017). Siebel Scholar (2016). The scientist who decided a delivery startup was a better bet than academia.
Dr. Hyo Min Park
CTO & Co-Founder
Co-inventor of CRISPR-12a technology licensed to Editas Medicine. SVP of Business Operations. The technical architect behind the NanoGalaxy platform's combinatorial discovery engine.

Their bet: build a combinatorial library of hydrophilic polymer nanoparticles - thousands of variants with different chemical structures - and screen them systematically for tissue-targeting properties. Not one delivery vehicle for everyone. A galaxy of options, each tuned for a specific destination in the body.

It was, and remains, a fundamentally different approach to the problem. Where lipid nanoparticles are a hammer that mostly reaches the liver, NanoGalaxy is a toolbox with a different instrument for every target tissue. The work is slow, chemistry-intensive, and not particularly glamorous. It is also, apparently, exactly what Roche and Sarepta and Lilly have been looking for.

2016
GenEdit Founded
Lee & Park spin out of UC Berkeley to build polymer nanoparticle delivery tech
2017
$8.5M Seed Round
DCVC Bio leads. Lee named Forbes 30 Under 30
2021
$26M Series A - Eli Lilly joins
Sequoia Capital, DCVC Bio, SK Holdings co-invest. Validates platform's pharma appeal
2022
$57M Sarepta Partnership
Gene editing for neuromuscular diseases across four indications
2023
Up to $644M Roche/Genentech Collaboration
$15M upfront + NIH TARGETED Challenge Phase I win (Dec 2023)
2024
$24M Series A1 led by Eli Lilly
Strategic deepening of Lilly relationship ahead of pipeline pivot
2025
First Roche Milestone Achieved
May 2025: first payment triggered in the $644M collaboration
2026
$60M Series B - GenEdit becomes BreezeBio
Rebrand signals pivot to internal therapeutic pipeline. BRZ-101 heads toward IND

NanoGalaxy: A Thousand Delivery Trucks, Each With a Different Address

The NanoGalaxy platform is not a single nanoparticle. It is a combinatorial library - think of it as a vast catalogue of molecular delivery vehicles, each engineered with subtly different hydrophilic polymer structures that give them distinct tissue-targeting properties. Some head to immune cells. Some find the heart. Some reach the lung. Some cross the blood-brain barrier into the CNS.

NanoGalaxy Platform

Combinatorial library of hydrophilic polymer nanoparticles. Delivers mRNA, siRNA, ASOs, proteins, and CRISPR components to immune cells, heart, lung, and CNS without triggering innate immunity. Can be re-dosed. Does not have an AAV's one-and-done limitation.

BRZ-101

Lead internal program for Type 1 Diabetes. Delivers mRNA-encoded autoantigens plus tolerogenic co-factors to antigen-presenting cells, inducing regulatory T cells (Tregs) to restore immune tolerance. Showed efficacy in mouse and non-human primate models. Advancing to IND.

Partner Discovery Engine

Custom nanoparticle discovery and optimization for pharmaceutical partners. Active programs with Roche/Genentech (autoimmune) and Sarepta (neuromuscular). Platform generates both upfront payments and long-term milestone revenue.

The key technical advantages over competing non-viral approaches are worth spelling out. First: no innate immune activation. The polymer chemistry looks nothing like biological entities, so the immune system ignores it - unlike lipid nanoparticles, which can trigger inflammatory responses at scale. Second: re-dosability. Because there is no viral shell for antibodies to lock onto, patients can receive repeat doses. Third: payload flexibility. NanoGalaxy can carry mRNA, siRNA, antisense oligonucleotides, therapeutic proteins, and CRISPR machinery. Fourth: tissue selectivity. The combinatorial screening process identifies which polymer variants reach which tissues in vivo - and with what efficiency.

Gene Delivery Technology Comparison - Key Capabilities
Tissue Targeting
NanoGalaxy: Multi-tissue
Tissue Targeting
LNPs: Liver-biased
Re-dosability
NanoGalaxy: Yes
Re-dosability
AAV: Limited by antibodies
Payload Size
NanoGalaxy: Flexible
Payload Size
AAV: ~4.7kb limit
Relative capability ratings based on published technical characteristics. NanoGalaxy advantages are particularly pronounced in re-dosability and multi-tissue targeting - the two areas where AAV and LNPs fall shortest for chronic disease applications.
Every polymer in the library is a hypothesis. Every tissue they can reach is another disease they can treat. BreezeBio's competitive moat is not a single molecule - it is a decade of hypotheses that turned out to be true.
On the NanoGalaxy combinatorial approach

Roche Does Not Write $644M Checks for Speculation

The best evidence that NanoGalaxy works is not in a paper. It is in the term sheets. Three separate partnerships with major pharmaceutical companies, each structured as a significant multi-year bet on the platform's ability to solve real delivery problems in real patients.

Roche / Genentech
Up to $644M to discover and develop nanoparticles delivering nucleic acid medicines for autoimmune disease. $15M upfront. First milestone achieved May 2025 - less than two years into the collaboration.
Sarepta Therapeutics
$57M partnership (2022) for gene editing therapeutics across four neuromuscular disease indications. Combines Sarepta's gene therapy infrastructure with BreezeBio's non-viral delivery.
Eli Lilly
Strategic investor in both Series A ($26M, 2021) and Series A1 ($24M, 2024). Two separate investment decisions from the same company is a vote of sustained confidence, not a one-time check.
Editas Medicine
Licensed BreezeBio's CRISPR-12a technology - the same IP co-invented by co-founder Hyo Min Park during her Berkeley PhD research.

The NIH TARGETED Challenge win in December 2023 matters here too - not because NIH grants move markets, but because it signals that independent scientific reviewers, not just industry deal-makers, evaluated the platform and concluded it was among the most promising programmable delivery approaches in development.

$118.5M in, Zero Approved Products Out - and That Is the Plan

BreezeBio's funding arc is unusual for a biotech: heavily international, with South Korean institutional investors making up a significant portion of the cap table alongside US venture stalwarts. The Series B in February 2026 was led by Yuanta Investment and DSC Investment, with six additional Korean funds participating alongside existing investors.

Series B
$60M
Feb 2026
Series A1
$24M
Jan 2024
Series A
$26M
Sep 2021
Seed
$8.5M
2017

The $118.5M in venture funding looks different when set against the partnership economics: the Roche deal alone is worth up to $644M in milestones. BreezeBio has effectively pre-sold portions of its future upside to fund the development of the platform that generates that upside. It is a coherent strategy, if you believe the platform works. Roche, Sarepta, and Lilly apparently do.

The Problem Has Not Been Solved - But the Delivery Has

BreezeBio's stated mission is to develop precision genetic medicines that reach the right tissue, deliver the right payload, and can be used more than once. That sounds modest until you realize how few companies can genuinely claim all three capabilities simultaneously.

Type 1 Diabetes affects approximately 8.4 million people worldwide, and the number is rising. It is an autoimmune disease - the immune system, confused, destroys the pancreatic cells that produce insulin. There is no cure. There is daily management. BRZ-101 is BreezeBio's attempt to change that calculus: instead of suppressing the immune system broadly (with the infection risks that entails), the therapy would re-educate it specifically, inducing the regulatory T cells that should have been preventing the attack in the first place.

If this works, it matters far beyond one indication. The same approach - using mRNA plus tolerogenic co-factors to restore immune specificity rather than shut down immunity - could apply to other autoimmune diseases: multiple sclerosis, lupus, rheumatoid arthritis. The mechanism is the same. Only the autoantigen changes.

The gene therapy field spent two decades learning to write genetic medicines. BreezeBio's contribution is learning to deliver the letter.
On BreezeBio's position in the genetic medicine ecosystem

This is what makes the delivery problem so important. Every genetic medicine - CRISPR, mRNA, siRNA, gene addition, gene silencing - depends on the payload reaching the right cell in the right tissue at sufficient concentration. Without precise delivery, the most elegant genetic payload is useless. BreezeBio is building the infrastructure on which a generation of genetic medicines will depend.

Field Notes

Back to Brisbane

Return to that lab in Brisbane. The polymer scientists are still running screens, still characterizing nanoparticles, still testing which molecular architecture reaches which tissue in a living system. The work looks the same as it did in 2016. But the context has changed entirely.

In 2016, GenEdit was a promising idea from two Berkeley PhDs with $8.5M and a thesis. In 2026, BreezeBio is a company with $118.5M in venture backing, pharmaceutical partnerships that could generate hundreds of millions in milestone payments, a lead therapeutic program heading toward human trials, and a platform that Roche - which has seen every gene therapy delivery approach on the market - chose as its partner for autoimmune nucleic acid medicines.

The delivery problem in gene therapy is not fully solved. No single company has cracked multi-tissue delivery, re-dosability, low immunogenicity, payload flexibility, and GMP-scalable manufacturing all at once. But BreezeBio is further along this checklist than almost anyone else in the non-viral space, and they have the partnership economics to prove it.

The scene in Brisbane has not changed. What has changed is what that work is now worth - and what it might enable for people with diseases that have been waiting, so far without a cure, for the mailroom to catch up with the medicine.

Go Deeper